KR890016046A - 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도 - Google Patents

2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도 Download PDF

Info

Publication number
KR890016046A
KR890016046A KR1019890004725A KR890004725A KR890016046A KR 890016046 A KR890016046 A KR 890016046A KR 1019890004725 A KR1019890004725 A KR 1019890004725A KR 890004725 A KR890004725 A KR 890004725A KR 890016046 A KR890016046 A KR 890016046A
Authority
KR
South Korea
Prior art keywords
dioxolane
compound according
group
hydroxymethyl
lower alkyl
Prior art date
Application number
KR1019890004725A
Other languages
English (en)
Other versions
KR0137023B1 (ko
Inventor
벨로우 버나드
Original Assignee
원본미기재
아이 에이 에프 바이오켐 인터내쇼날, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22657287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890016046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 아이 에이 에프 바이오켐 인터내쇼날, 인코오포레이티드 filed Critical 원본미기재
Publication of KR890016046A publication Critical patent/KR890016046A/ko
Application granted granted Critical
Publication of KR0137023B1 publication Critical patent/KR0137023B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Paints Or Removers (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

내용 없음

Description

2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기식(L)의 1,3-디옥솔란, 이것의 기하학적 및 광학이성체 및 그 이성체의 혼합물.
    상기식에서, R1은 수소, 1-16개의 탄소원자를 함유한 아실기, 벤조일 및 적어도 하나의 할로겐, 저급알킬, 저급알콕시, 니트로 및 트리플루오로메틸기에 의해 치환된 벤조일로 구성되는 그룹으로 부터 선택되며 ; R2는 하기 라디칼로 부터 선택된 헤테로시클릭 라디칼이며,
    R3및 R4는 수소 및 저급알킬로 구성되는 그룹으로 부터 각각 선택되며 ; R5는 저급알킬 및 할로겐으로 구성되는 그룹으로 부터 선택된다.
  2. 제 1 항에 있어서, 2-아세톡시메틸-4-(티미딘-1'-일)-1,3-디옥솔란인 화합물.
  3. 제 1 항에 있어서, 2-히드록시메틸-4-(티미딘-1'-일)-1.3-디옥솔란인 화합물.
  4. 제 1 항에 있어서, 2-벤조일 옥시메틸-4-(시토신-1'-일)-1,3-디옥솔란인 화합물.
  5. 제 1 항에 있어서, 트란스-2-하이드로메틸-4-시토신-1'-일)-1,3-디옥솔란인 화합물.
  6. 제 1 항에 있어서, 2-벤조일옥시메틸-4-(아데노신-9'-일)-1,3-디옥솔란인 화합물.
  7. 제 1 항에 있어서, 2-히드록시메틸-4-(아데노신-9')-1,3-디옥솔란인 화합물.
  8. 제 1 항에 있어서, 2-벤조일옥시메틸-4-(2'-아미노-6'-클로로-(푸린-9'-일))-1,3-디옥솔란인 화합물.
  9. 제 1 항에 있어서, 2-히드록시메틸-4-(2'-아미노-6'-클로로-(푸린-9'-일))-1,3-디옥솔란인 화합물.
  10. 제 1 항에 있어서, 2-히드록시메틸-4-(2'-아미노-푸린-9')-1,3-디옥솔란인 화합물.
  11. 제 1 항에 있어서, 2-히드록시메틸-4-(2',6'-디아미노-푸린-9'-일)-1,3-디옥솔란인 화합물.
  12. 제 1 항에 있어서, 2-히드록시메틸-4-(구아니딘-9'-일)-1,3-디옥솔란인 화합물.
  13. 치료학적 유효양의 하기식(L)의 2-치환-4-1,3-디옥솔란, 이것의 기하학적 및 광학 이성질체 및 이것의 이성체 혼합물을 감염된 숙주에 투여하는 것으로 구성되는 비루스 감염의 치료 방법 .
    상기식에서, R1은 수소, 1-16개의 탄소원자를 함유한 아실기, 벤조일 및 적어도 하나의 할로겐, 저급알킬, 저급알콕시, 니트로 및 트리플루오로메틸 기로 치환된 벤조일로 구성되는 그룹으로 부터 선택되며 , R2는 하기 라디칼로 부터 선택된 헤테로시클릭라디칼이며
    R3및 R4는 수소 및 저급알킬로 구성되는 그룹으로 부터 각각 선택되며 R5는 저급알킬 및 할로겐으로 구성되는 그룹으로 부터 선택된다.
    ※ 참고사항 :최초출원 내용에 의하여 공개하는 것임.
KR1019890004725A 1988-04-11 1989-04-11 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도 KR0137023B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17961588A 1988-04-11 1988-04-11
CA179615 1988-04-11

Publications (2)

Publication Number Publication Date
KR890016046A true KR890016046A (ko) 1989-11-28
KR0137023B1 KR0137023B1 (ko) 1998-04-25

Family

ID=22657287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890004725A KR0137023B1 (ko) 1988-04-11 1989-04-11 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도

Country Status (16)

Country Link
EP (1) EP0337713B1 (ko)
JP (1) JP3085675B2 (ko)
KR (1) KR0137023B1 (ko)
AT (1) ATE129247T1 (ko)
AU (1) AU631786B2 (ko)
CA (1) CA1339609C (ko)
DE (1) DE68924549T2 (ko)
DK (1) DK175372B1 (ko)
ES (1) ES2078234T3 (ko)
GR (1) GR3017812T3 (ko)
HK (1) HK5996A (ko)
IE (1) IE71225B1 (ko)
IL (1) IL89921A (ko)
NZ (1) NZ228645A (ko)
OA (1) OA09470A (ko)
ZA (1) ZA892645B (ko)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597824A (en) * 1987-11-03 1997-01-28 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
IE904378A1 (en) 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ATE143016T1 (de) * 1990-11-13 1996-10-15 Iaf Biochem Int Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO1998041522A1 (en) 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
EA008609B1 (ru) 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
ES2232169T3 (es) 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE315574T1 (de) 1998-11-05 2006-02-15 Centre Nat Rech Scient Nukleoside mit anti-hepatitis b virus wirkung
ATE254126T1 (de) 1998-12-23 2003-11-15 Shire Biochem Inc Antivirale nukleosidanaloga
CN1297281C (zh) 1999-03-29 2007-01-31 希拉生物化学股份有限公司 治疗白血病的方法
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
DE60011637T2 (de) * 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
WO2001032153A2 (en) * 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1600451A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-l-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
HUP0301363A2 (hu) * 2000-10-13 2005-12-28 Shire Biochem Inc. Javított intercelluláris bejuttathatóságú dioxolán analógok
CA2788498C (en) 2001-03-01 2016-02-16 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
US7785839B2 (en) 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
AU2006294807B2 (en) 2005-09-26 2013-01-17 Gilead Pharmasset Llc Modified 4'-nucleosides as antiviral agents
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
WO2009051848A1 (en) 2007-10-20 2009-04-23 Kinex Pharmaceuticals, Llc Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.

Also Published As

Publication number Publication date
EP0337713A3 (en) 1990-11-22
GR3017812T3 (en) 1996-01-31
DK172089D0 (da) 1989-04-10
NZ228645A (en) 1991-09-25
OA09470A (en) 1992-11-15
ATE129247T1 (de) 1995-11-15
JPH01316375A (ja) 1989-12-21
JP3085675B2 (ja) 2000-09-11
IE891136L (en) 1989-10-11
AU631786B2 (en) 1992-12-10
HK5996A (en) 1996-01-19
DE68924549D1 (de) 1995-11-23
IE71225B1 (en) 1997-02-12
ZA892645B (en) 1989-12-27
EP0337713B1 (en) 1995-10-18
DK172089A (da) 1989-10-12
IL89921A0 (en) 1989-12-15
AU3264489A (en) 1989-10-12
CA1339609C (en) 1997-12-30
ES2078234T3 (es) 1995-12-16
EP0337713A2 (en) 1989-10-18
DE68924549T2 (de) 1996-04-04
DK175372B1 (da) 2004-09-13
IL89921A (en) 1993-08-18
KR0137023B1 (ko) 1998-04-25

Similar Documents

Publication Publication Date Title
KR890016046A (ko) 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도
ATE126517T1 (de) Verwendung von bis(3,4- dialkylbenzyliden)sorbitolacetale und diese enthaltende zusammensetzungen.
FI96027C (fi) (Bentsylideeni) -atsolyylimetyylisykloalkaanit ja niiden käyttö fungisideina
ECSP941066A (es) Derivados de 1.5 benzodiazepina
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
SE7902794L (sv) Nya karbostyrilderivat och forfarande for framstellning derav
ATE24001T1 (de) Substituierte 1-hydroxyethyl-triazolyl-derivate.
BE1003230A3 (fr) Nouveaux derives du benzotriazole, leur preparation et leur utilisation comme absorbants u.v.
SE8503415D0 (sv) Novel isoindolinyl-alkyl-piperazines
ES2061487T3 (es) Compuestos macrolidos.
FI912400A (fi) Isomakromanderivat.
ATE85337T1 (de) Makrolid-verbindungen.
KR830006403A (ko) 광학적 광택제 혼합물
ATE13532T1 (de) Poly(piperidylamin)alkane und damit stabilisierte synthetische harzzusammensetzungen.
ATE92066T1 (de) Sulfonyldecahydro-8h-isochino(2,1g>(1,6>naphthyridine, optische isomere davon und verwandte verbindungen.
FI861934A0 (fi) Nya isoxazolderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
SE7909751L (sv) 4,1-bensoxazepiner och tia-analoger derav
DE3362036D1 (en) Ketene-o,o-acetates and process for their preparation
ATE384149T1 (de) Hydrophilieadditive
ES448439A1 (es) Procedimiento para la preparacion de nuevos de diacina.
SE8701524L (sv) Nya sulfonamider och deras framstaellningsfoerfarande
SE8000138L (sv) Nya 3-cyklopentan-1,2'(1'h)-naftalen-derivat, framstellning derav och lekemedel innehallande desamma
DK200200474A (da) 1,3-dioxolanderivater
RU93005237A (ru) Производные тиазолоизоиндолинона, обладающие антивирусной активностью

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120126

Year of fee payment: 15

EXPY Expiration of term